Abstract
The progressive neurodegenerative process in Parkinson's disease (PD) is not restricted to dopaminergic midbrain neurons but involves the entire nervous system. In this review, we outline established treatment options at different disease stages and address new therapeutic approaches. These include, based on recent advances in the understanding of the pathophysiology of PD, genetic and disease-modifying approaches to reduce abnormal accumulation and aggregation of alpha-synuclein (aSYN), mitochondrial dysfunction, and dysfunction of lysosomal proteins. Moreover, we highlight clinical trials to reduce neuroinflammation and increase neurorestoration.
Cite
CITATION STYLE
Zeuner, K. E., Schäffer, E., Hopfner, F., Brüggemann, N., & Berg, D. (2019, May 1). Progress of Pharmacological Approaches in Parkinson’s Disease. Clinical Pharmacology and Therapeutics. Nature Publishing Group. https://doi.org/10.1002/cpt.1374
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.